3Wildemeersch D, Pylyser K, DeWever N, et al. Endometrial safety after 5 years of continuous combined transdermal estrogen and intrauterine levonorgestrel delivery for postmenopausal hormone substitution [ J ]. Maturitas, 2007,57 : 205-211.
4Kriplani A, Singh BM, Lal S, et al. Efficacy, acceptability and side effects of the levonorgestrel intrauterine system formenorrhagia[ J ]. Int J Gynaecol Obstet, 2007,97 : 190- 197.
6Luukkainen T, Pakarinen P, Toivonen J. Progestin-releasing intra-uterine systems [ J ]. Semin Reprod Med,2001, 19:355-363.
7Xiao B, Zeng T, Wu S, et al. Effect of levonorgestrual-releasing intrauterine device on hormonal profile and menstrual pattern after long-term use [ J ]. Contrception, 1995, 51:359-365.
6Sivin I, Stem J. Health during prolonged use of levonorgestrel 20 mierograms/d and the copper TCu 380Ag intrauterine contraceptive devices: a muhicenter study. International Committee for Contraception Research (ICCR) [J]. Fertil Steril, 1994, 61(1) :70-77.
7Varita E, Wahlstrom T, Rauramo I. A 5-year follow-up study on the use of a levonorgestrel intrauterine system in women receiving hormone replacement therapy[ J]. Fertil Steril, 2001, 76(5) :969-973.
8McGavigan C J, Dockery P, Metaxa-Mariatou V, et al. Hormonally mediated disturbance of angiogenesis in the human endometrium after exposure to intrauterine levonorgestrel[ J]. Hum Reprod, 2003, 18 (1) :77-84.
9Jondet M, Letellier B, Verdys MT. Endometrial vascularization in levonorgestrel intrauterine device users; computerized microvessel measurement study [ J ]. Contraception, 2005, 71 ( 1 ) :60-64.
10Wildemeersch D, Pylyser K, De Wever N et al. Endometrial safety after 5 years of continuous combined transdermal estrogen and intrauterine levonorgestrel delivery for postmenopausal hormone substitution [J] . Maturitas, 2007, 57 (2): 205
